<DOC>
	<DOCNO>NCT00662571</DOCNO>
	<brief_summary>In 2004 , acamprosate approve U.S. abstinence maintenance , decrease craving , alcoholic patient undergone detoxification . new anti-craving drug encouraging , 36.1 % subject treat acamprosate remain abstinent 6 month . Having ability identify treatment responsive individual would major impact use acamprosate .</brief_summary>
	<brief_title>Acamprosate : Genes Associated With Response</brief_title>
	<detailed_description>The primary objective pharmacogenomic probe study acamprosate identify genetic variation predict response . Our hypothesis effective acamprosate response alcohol dependent subject may influence genetically control variation functionality N-methyl-D-aspartate receptor ( NMDA ) and/or type 5 metabotropic glutamate receptor ( mGluR5 ) . Hypothesis confirmation could lead development effective individualized treatment recommendation alcohol dependent patient base pharmacogenomically relevant genetic variation . The general goal identify genetic polymorphic variant differentiate subject continuously abstinent six month take acamprosate relapse subject . The initial analysis determine whether ten polymorphism four target gene ( GRIN1 , GRIN2A GRIN2B code NMDA receptor GRM5 cod type mGluR5 receptor ) associate successful abstinence . Subsequent analysis examine whether variation comprehensive set 383 linkage disequilibrium haplotype tag single nucleotide polymorphisms four gene predict successfully abstinent subject .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>1 . Male female , Age 1880 . 2 . 2 . Primary diagnosis alcohol dependence base DSMIVTR criterion determine Psychiatric Research Interview Substance Mental Disorders ( PRISM ) ( stable mood anxiety disorder exclusionary ) . 3 . Prior enrollment IRB approve protocol `` Developing DNA Repository Genomic Studies Addiction : A Pilot Study '' . 1 . Inability provide inform consent . 2 . Inability speak English . 3 . History hypersensitivity allergic reaction acamprosate . 4 . Moderate severe renal impairment , determine creatinine level &gt; 1.5 mg/dL . 5 . Diagnosis primary biliary cirrhosis , chronic active hepatitis , druginduced hepatic insufficiency , note medical record . 6 . Women pregnant , lactating , plan become pregnant next year . 7 . Any unstable active medical additional psychiatric condition determine investigator . 9 . Active suicidal ideation determine response provide PRISM determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>nucleotide polymorphism</keyword>
	<keyword>disequilibrium haplotype</keyword>
	<keyword>acamprosate</keyword>
	<keyword>differentiate</keyword>
	<keyword>pharmacogenomic</keyword>
	<keyword>effective individualize treatment</keyword>
	<keyword>alcohol dependent</keyword>
	<keyword>N-methyl-D-aspartate receptor ( NMDA )</keyword>
	<keyword>metabotropic glutamate receptor</keyword>
	<keyword>decrease crave</keyword>
	<keyword>abstinence maintenance</keyword>
</DOC>